Global Health Funding Analysis in FY 2027 NSRP Appropriations Bill

On April 22, 2026, the U.S. House Appropriations Committee released its Fiscal Year (FY) 2027 National Security, Department of State, and Related Programs (NSRP) Appropriations Bill, outlining discretionary funding for global health programs. The proposed budget reflects a complex balancing act between fiscal constraints and ongoing public health priorities, particularly in the fight against HIV/AIDS and other infectious diseases. While the bill increases overall funding compared to the President’s budget request, it also introduces reductions in key areas, raising concerns among global health advocates about the potential impact on long-standing initiatives.

Global Health Programs Funding Overview

The bill allocates $8.9 billion to the Global Health Programs (GHP) account, which serves as the primary funding mechanism for U.S. Global health efforts. This represents a $532 million decrease from the FY 2026 enacted level of $9.4 billion but a substantial $3.8 billion increase over the President’s FY 2027 budget request of $5.1 billion. The GHP account is divided into two main funding envelopes: one for the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), and another for other global health activities, including programs historically managed by the U.S. Agency for International Development (USAID).

PEPFAR and Bilateral HIV Funding: A Mixed Picture

The bill provides $5.53 billion for PEPFAR, the cornerstone of U.S. Efforts to combat HIV/AIDS globally. Within this total, $4.28 billion is allocated for bilateral HIV programs, which support direct country-level interventions such as antiretroviral therapy, prevention programs, and health system strengthening. This represents an $350 million reduction—an 8% decrease—from the FY 2026 enacted level of $4.63 billion. The reduction in bilateral HIV funding is the only specific program area to see a decrease compared to the previous fiscal year.

The FY 2027 President’s budget request had proposed a significant restructuring of global health funding, including the elimination of disease-specific accounts in favor of a more flexible approach to address country-level needs. However, the House bill maintains separate funding lines for key programs, including PEPFAR and the Global Fund, while still reflecting some of the administration’s proposed shifts in funding priorities.

Global Fund Contribution Remains Flat

The bill specifies a U.S. Contribution of $1.25 billion to the Global Fund, matching the FY 2026 enacted level. This flat funding contrasts with the President’s FY 2027 budget request, which did not include a specific dollar amount for the Global Fund but instead committed to leveraging $2 from other donors for every $1 contributed by the United States, with a cap of 33% of total Global Fund contributions. The House bill’s explicit funding level provides clarity for the Global Fund’s planning but does not reflect an increase to match rising global needs.

Other Global Health Activities: Funding Unspecified

The bill allocates $3.37 billion to the second funding envelope, which covers other global health activities historically managed by USAID. This category includes programs addressing malaria, tuberculosis, polio, family planning, nutrition, and neglected tropical diseases. However, the bill does not provide detailed breakdowns for these individual programs, leaving their specific funding levels unclear. The President’s FY 2027 budget request had proposed eliminating disease-specific accounts entirely, a move that would have given the State Department greater flexibility to allocate funds based on evolving needs but also raised concerns about reduced transparency and accountability for individual health priorities.

The bill’s language suggests that additional funding for HIV programs may be drawn from this broader envelope, though the exact distribution remains unspecified. This ambiguity could complicate efforts to assess the bill’s impact on specific health initiatives, particularly those that have historically relied on dedicated funding streams.

Implications for Global Health Priorities

The proposed funding levels in the House bill carry significant implications for global health programs, particularly in the context of ongoing efforts to combat HIV/AIDS. PEPFAR, which has been credited with saving over 25 million lives since its launch in 2003, has faced growing challenges in recent years, including funding constraints, shifting political priorities, and the need to adapt to evolving epidemics. The 8% reduction in bilateral HIV funding could strain efforts to maintain treatment coverage, expand prevention programs, and support health systems in high-burden countries.

The flat funding for the Global Fund, while providing stability, may also limit the organization’s ability to scale up its efforts to combat HIV, tuberculosis, and malaria. The Global Fund has set ambitious targets for 2023-2028, including saving 20 million lives, averting 450 million infections, and reducing the mortality rate of the three diseases by 64%. Achieving these goals will require sustained and increased financial commitments from donor countries, including the United States.

The bill’s approach to other global health activities—particularly the lack of detailed funding breakdowns—reflects a broader trend toward consolidating health funding under broader categories. While this may offer greater flexibility to respond to emerging health threats, it also risks sidelining programs that lack strong political or public advocacy. For example, the President’s FY 2027 budget request explicitly eliminated funding for family planning and reproductive health, a move that could have far-reaching consequences for maternal and child health outcomes in low- and middle-income countries.

Next Steps and Uncertainties

The House Appropriations Committee’s bill is the first step in a lengthy budget process that will involve negotiations with the Senate and the White House. The final funding levels for global health programs will depend on these discussions, as well as broader fiscal and political considerations. Advocates for global health funding are likely to push for increases in key areas, particularly bilateral HIV funding and contributions to the Global Fund, to ensure that progress in combating infectious diseases is not reversed.

One of the key uncertainties is how the bill’s funding structure will affect the implementation of global health programs on the ground. The lack of detailed breakdowns for programs outside of PEPFAR and the Global Fund could create challenges for USAID and other implementing agencies, which may need to make difficult trade-offs between competing health priorities. The bill’s emphasis on flexibility could lead to shifts in funding away from disease-specific programs, potentially impacting the continuity of care for millions of people who rely on U.S.-supported health services.

As the budget process moves forward, stakeholders will be closely watching how these funding decisions align with broader U.S. Foreign policy and global health goals. The outcome will have significant implications not only for the health of populations in low- and middle-income countries but also for the United States’ role as a leader in global health security and pandemic preparedness.

Conclusion

The FY 2027 House Appropriations Committee bill represents a critical juncture for U.S. Global health funding. While the proposed $8.9 billion for the Global Health Programs account reflects a commitment to maintaining robust support for international health initiatives, the reductions in bilateral HIV funding and the lack of clarity around other program areas raise important questions about the future of U.S. Leadership in global health. As the budget process unfolds, the decisions made in the coming months will shape the trajectory of efforts to combat HIV/AIDS, tuberculosis, malaria, and other pressing health challenges for years to come.